FDA approves Novartis IL-17A monoantiticx for treatment of non-radiation siegenle spinal arthritis

The FDAapproved Novartis' fourth anti-IL-17A monoantiticcos (secukinumab) for the treatment of adult patients with non-radiation axial spinal arthritisThe FDA approved Lilly's Taltz just a few weeks ago, becoming the first IL-17 monotophode for the apparesationNovartis says Cosentyx is now involved in the disease, which affects more than 1 million patients in the United States each yearThe FDA's approval is based on the results of a phase 3 clinical study that showed That Cosentyx significantly reduced symptoms of the disease compared to a placebo for four months and one year after treatmentMore than 35 percent of patients treated with Cosentyx had symptoms at 52 weeks, compared with 19 percent of those who took a placeboAt week 16, 42.2 percent of patients reached this level, compared with 29.2 percent of placebosCosentyx received approval from the European MedicinesAdministrationAgency in April for the treatment of non-radiation axial spinal arthritis and has submitted approval to regulators in Japan